{"id":"menacwy","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Injection site pain"},{"rate":"10-25","effect":"Injection site erythema"},{"rate":"10-20","effect":"Injection site swelling"},{"rate":"5-15","effect":"Fever"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:22:09.321181","_dailymed":{"setId":"fd5652b6-5ae4-437e-a456-47deaf500794","title":"PENBRAYA (MENINGOCOCCAL GROUPS A, B, C, W, AND Y VACCINE) KIT [PFIZER LABORATORIES DIV PFIZER INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsules from Neisseria meningitidis serogroups A, C, W, and Y conjugated to a protein carrier (CRM197), which enhances immunogenicity and T-cell dependent immune responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these four serogroups.","oneSentence":"MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:18.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in infants, children, adolescents, and adults"}]},"_fixedFields":["pubmed(457)"],"trialDetails":[{"nctId":"NCT06523231","phase":"PHASE2","title":"Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2025-04-07","conditions":"Shigellosis","enrollment":110},{"nctId":"NCT07379151","phase":"","title":"Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2026-03","conditions":"Meningoccocal Disease","enrollment":450},{"nctId":"NCT05919472","phase":"NA","title":"Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women","status":"COMPLETED","sponsor":"Nicole Stoffel","startDate":"2023-07-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT04999267","phase":"NA","title":"Increasing Vaccine Uptake Among Adolescents in the Rural South","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-08-31","conditions":"Vaccine Hesitancy","enrollment":2},{"nctId":"NCT04400838","phase":"PHASE2, PHASE3","title":"Investigating a Vaccine Against COVID-19","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-05-28","conditions":"Coronavirus","enrollment":10811},{"nctId":"NCT04324606","phase":"PHASE1, PHASE2","title":"A Study of a Candidate COVID-19 Vaccine (COV001)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-04-23","conditions":"Coronavirus","enrollment":1077},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT03929757","phase":"PHASE2","title":"A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-08-19","conditions":"Ebola Virus Disease","enrollment":108},{"nctId":"NCT05006833","phase":"NA","title":"Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2021-11-18","conditions":"HPV","enrollment":21110},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT05873751","phase":"","title":"A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-04-24","conditions":"Gonorrhea, Chlamydia, Meningococcal Vaccines","enrollment":1307378},{"nctId":"NCT04318548","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-25","conditions":"Infections, Meningococcal","enrollment":945},{"nctId":"NCT04056117","phase":"PHASE1, PHASE2","title":"A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2019-09-02","conditions":"Shigellosis","enrollment":596},{"nctId":"NCT04707391","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-25","conditions":"Meningitis, Meningococcal","enrollment":1250},{"nctId":"NCT04819113","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-04-09","conditions":"Meningococcal Vaccine","enrollment":149},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT06116669","phase":"NA","title":"Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women","status":"UNKNOWN","sponsor":"Swiss Federal Institute of Technology","startDate":"2023-11-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT01725217","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-11","conditions":"Meningococcal Disease","enrollment":198},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT04239430","phase":"","title":"Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2020-11-26","conditions":"HIV/AIDS, Meningococcal Disease","enrollment":55},{"nctId":"NCT01939158","phase":"PHASE3","title":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-02","conditions":"Infections, Meningococcal","enrollment":803},{"nctId":"NCT03433482","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-30","conditions":"Meningitis, Meningococcal","enrollment":1707},{"nctId":"NCT03652610","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-07","conditions":"Infections, Meningococcal","enrollment":996},{"nctId":"NCT04536051","phase":"PHASE3","title":"A Study of a Candidate COVID-19 Vaccine (COV003)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2020-06-02","conditions":"Coronavirus","enrollment":10300},{"nctId":"NCT03189745","phase":"PHASE3","title":"A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-08-01","conditions":"Meningococcal ACWY Disease","enrollment":229},{"nctId":"NCT01192997","phase":"PHASE2, PHASE3","title":"Comparison of Two Meningococcal ACWY Conjugate Vaccines","status":"COMPLETED","sponsor":"Public Health England","startDate":"2012-06","conditions":"Meningococcal Meningitis","enrollment":91},{"nctId":"NCT02451514","phase":"PHASE2","title":"A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-30","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":129},{"nctId":"NCT01272180","phase":"PHASE2","title":"Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-08","conditions":"Invasive Meningococcal Disease","enrollment":484},{"nctId":"NCT03587207","phase":"PHASE2","title":"Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-09","conditions":"Meningitis, Meningococcal","enrollment":520},{"nctId":"NCT02986854","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-08","conditions":"Infections, Meningococcal","enrollment":704},{"nctId":"NCT02287688","phase":"","title":"Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-01","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":144},{"nctId":"NCT01934140","phase":"PHASE3","title":"Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Infections, Meningococcal","enrollment":311},{"nctId":"NCT02446691","phase":"PHASE4","title":"Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-13","conditions":"Infections, Meningococcal","enrollment":128},{"nctId":"NCT00471081","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-05","conditions":"Infections, Meningococcal","enrollment":385},{"nctId":"NCT01900899","phase":"PHASE3","title":"Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Infections, Meningococcal","enrollment":184},{"nctId":"NCT01682876","phase":"PHASE3","title":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-07","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":715},{"nctId":"NCT01962207","phase":"PHASE3","title":"The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Infections, Meningococcal","enrollment":243},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT00329849","phase":"PHASE3","title":"Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-05","conditions":"Meningococcal Disease","enrollment":1500},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT01547715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India","status":"COMPLETED","sponsor":"Novartis","startDate":"2012-03","conditions":"Bacterial Meningitis","enrollment":180},{"nctId":"NCT01214837","phase":"PHASE3","title":"Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":751},{"nctId":"NCT02285777","phase":"PHASE2","title":"Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-01","conditions":"Meningococcal Disease","enrollment":189},{"nctId":"NCT01766206","phase":"PHASE4","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-15","conditions":"Meningococcal Disease","enrollment":3948},{"nctId":"NCT02140762","phase":"PHASE2","title":"Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-05","conditions":"Meningococcal Disease","enrollment":305},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT02106390","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-05","conditions":"Infections, Meningococcal","enrollment":750},{"nctId":"NCT00356369","phase":"PHASE2","title":"Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-23","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT00262041","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-10","conditions":"Prevention of Meningococcal Disease","enrollment":524},{"nctId":"NCT01345721","phase":"PHASE3","title":"Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Meningococcal Disease","enrollment":205},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT01767376","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-10","conditions":"Infections, Meningococcal","enrollment":692},{"nctId":"NCT01148017","phase":"PHASE3","title":"Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-07","conditions":"Meningococcal Meningitis","enrollment":433},{"nctId":"NCT00856297","phase":"PHASE3","title":"Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-02","conditions":"Meningococcal Meningitis","enrollment":389},{"nctId":"NCT01453348","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-10","conditions":"Meningococcal Disease, Meningococcal Meningitis, Hepatitis A","enrollment":252},{"nctId":"NCT01705379","phase":"","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older","status":"WITHDRAWN","sponsor":"Novartis Vaccines","startDate":"2013-03","conditions":"Meningococcal Disease","enrollment":""},{"nctId":"NCT01593514","phase":"PHASE4","title":"Understanding the Immune Response to Two Different Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-12","conditions":"Meningitis, Meningococcal Disease, Septicaemia","enrollment":20},{"nctId":"NCT01992536","phase":"PHASE2","title":"Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-12","conditions":"Meningococcal Disease","enrollment":194},{"nctId":"NCT00126984","phase":"PHASE2","title":"Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"Infections, Meningococcal","enrollment":508},{"nctId":"NCT00126945","phase":"PHASE2","title":"Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08","conditions":"Infections, Meningococcal","enrollment":125},{"nctId":"NCT00196963","phase":"PHASE2","title":"Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Infections, Meningococcal","enrollment":125},{"nctId":"NCT00196950","phase":"PHASE2","title":"Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09","conditions":"Infections, Meningococcal","enrollment":50},{"nctId":"NCT00518180","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis","enrollment":1620},{"nctId":"NCT01214850","phase":"PHASE3","title":"Novartis Vaccine and Diagnostics Carriage Trial","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"N. Meningitidis Carriage","enrollment":2968},{"nctId":"NCT00560313","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":54},{"nctId":"NCT00616421","phase":"PHASE3","title":"Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Infections","enrollment":2907},{"nctId":"NCT00262028","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-04","conditions":"Prevention of Meningococcal Disease","enrollment":910},{"nctId":"NCT00310817","phase":"PHASE2","title":"Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-03","conditions":"Meningococcal Meningitis","enrollment":623},{"nctId":"NCT01994629","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":202},{"nctId":"NCT01973218","phase":"PHASE3","title":"Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":264},{"nctId":"NCT01452438","phase":"","title":"Safety Surveillance of MenACWY-CRM Vaccine in Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Meningococcal Disease","enrollment":393},{"nctId":"NCT01018732","phase":"PHASE2","title":"A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-01","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":155},{"nctId":"NCT01452464","phase":"","title":"Safety of MenACWY-CRM Vaccination in Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Meningococcal Disease","enrollment":55397},{"nctId":"NCT00450437","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningococcal Infections, Meningococcal Meningitis","enrollment":3539},{"nctId":"NCT00901940","phase":"PHASE3","title":"Understanding the Immune Response to Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-06","conditions":"Meningitis, Septicemia","enrollment":150},{"nctId":"NCT00715910","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Infections, Meningococcal","enrollment":818},{"nctId":"NCT01367158","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-07","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":440},{"nctId":"NCT00601731","phase":"PHASE2","title":"Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Meningococcal Disease","enrollment":382},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT01410474","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-08","conditions":"Bacterial Meningitis","enrollment":341},{"nctId":"NCT01823536","phase":"PHASE4","title":"Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Meningococcal Disease","enrollment":465},{"nctId":"NCT00329901","phase":"PHASE3","title":"Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-04","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1072},{"nctId":"NCT00262002","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Prevention of Meningococcal Disease","enrollment":601},{"nctId":"NCT00474487","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-05","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":2831},{"nctId":"NCT01000311","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-11","conditions":"Meningococcal Disease","enrollment":529},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT01424644","phase":"PHASE4","title":"A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-09","conditions":"Meningococcal Meningitis","enrollment":801},{"nctId":"NCT00667602","phase":"PHASE3","title":"Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Meningitis","enrollment":662},{"nctId":"NCT00806195","phase":"PHASE3","title":"Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-12","conditions":"Meningitis, Meningococcal Infection","enrollment":7744},{"nctId":"NCT00626327","phase":"PHASE3","title":"Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Meningococcal Infections","enrollment":1630},{"nctId":"NCT01274897","phase":"PHASE3","title":"A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-12","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":450},{"nctId":"NCT01210885","phase":"PHASE2","title":"Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-12","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":495}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":457,"recentPublications":[{"date":"2026 Mar 6","pmid":"41792337","title":"Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6-23 months: phase III study (US/Puerto Rico).","journal":"Pediatric research"},{"date":"2026 Mar 6","pmid":"41790381","title":"Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal Vaccine Schedule in the United States.","journal":"PharmacoEconomics"},{"date":"2026","pmid":"41785285","title":"Meningococcal carriage and transmission dynamics in college students in Louisville, Kentucky.","journal":"PloS one"},{"date":"2026 Feb 4","pmid":"41746073","title":"Evaluation of the MenACWY Vaccination Catch-Up Campaign Among Adolescents in Madrid: Coverage, Trends, and Determinants.","journal":"Vaccines"},{"date":"2026 Apr 2","pmid":"41722530","title":"Evaluation of the impact of different notification methods for unvaccinated individuals in a ACWY meningococcal vaccination campaign.","journal":"Vaccine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Menveo"],"phase":"marketed","status":"active","brandName":"MenACWY","genericName":"MenACWY","companyName":"LimmaTech Biologics AG","companyId":"limmatech-biologics-ag","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}